Evidon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evidon

Property Description
Active Ingredient Alpha-Tocopherol (Vitamin E)
Form Oral Gel Capsule, Oral Solution (Drops)
Pharmacological Class Fat-Soluble Vitamin; Antioxidant
General Purpose Prevention of Vitamin E deficiency
Origin Natural (D-alpha-Tocopherol) or Synthetic (DL-alpha-Tocopherol)

Evidon: Classification as a Fat-Soluble Vitamin

Evidon is a medicinal preparation whose active component is Alpha-Tocopherol, the specific form of Vitamin E considered the most essential for human health. It is formally classified as a fat-soluble vitamin and an essential nutrient, a compound the body requires but cannot synthesize internally, necessitating intake from external sources. The active ingredient can be sourced as the naturally occurring form (D-alpha-Tocopherol) or the synthetic form (DL-alpha-Tocopherol), with both types providing the necessary nutritional support to prevent a state of Vitamin E deficiency. The role of Vitamin E in human nutrition is widely recognized in clinical practice and supported by decades of pharmacological studies.


Composition and Available Forms of Evidon

Evidon is typically formulated as an oral medicine, supplied either in a gel capsule or as a liquid solution (drops). Since Alpha-Tocopherol is inherently fat-soluble, the active ingredient is consistently dissolved in a lipid vehicle (such as medium-chain triglycerides or an inert oil) to ensure its chemical stability and proper absorption. This formulation method guarantees that the nutrient can be effectively absorbed from the digestive tract and utilized systemically. This oil-based approach is necessary as fat-soluble compounds require incorporation into lipid carriers for proper delivery throughout the body.


Evidon’s Primary Role as an Antioxidant

The general purpose of Evidon is to maintain cellular integrity by functioning as a primary chain-breaking antioxidant within the body. Its key mechanism involves directly integrating into the lipid layer of cell membranes, where it intercepts highly reactive molecules called free radicals. By neutralizing these unstable molecules, Evidon effectively stops the damaging process of lipid peroxidation. This function is crucial for safeguarding essential cells in the nervous system and red blood cells from structural damage, a benefit that is universally acknowledged in biochemistry research.

Regulatory References

  1. NIH MedlinePlus: Vitamin E

What side effects are possible with Evidon?

Possible Side Effects and Safety Information

The official safety profile of Evidon (Alpha-Tocopherol) is structured according to government regulatory standards, classifying adverse reactions by frequency and physiological system. This information defines the medicine's documented risk profile without providing medical instruction.


Adverse Reaction Scope

The most frequently classified reactions fall into the Gastrointestinal disorders (e.g., diarrhoea, abdominal pain) and Skin and subcutaneous tissue disorders (e.g., rash, pruritus). Diarrhoea is commonly noted, while effects such as alopecia, pruritus, and headache are generally classified as Uncommon.

Category Official Regulatory Classification
Common Effects Diarrhoea
Uncommon Effects Alopecia, Pruritus, Rash, Headache

Serious Safety Constraints

The most clinically significant safety characteristic documented in regulatory sources is the increased risk of bleeding or haemorrhage, which is primarily associated with high-dose exposure. This concern extends to the risk of hemorrhagic stroke and requires careful consideration in patients receiving anticoagulant medications.


Population-Specific Notes

The official label documents specific risks for certain groups. Caution is required for patients with pre-existing renal or hepatic impairment. Furthermore, specific high-dose formulations have been associated with a higher incidence of necrotising enterocolitis in low-weight premature infants.

This structure ensures transparency regarding documented risks, classifying them by frequency and context, as required by regulatory authorities.

Overdose and Emergency Response

The overdose profile for Evidon (Alpha-Tocopherol) is defined by manifestations primarily associated with prolonged periods of high-dose supplementation. Documented toxicity presentations commonly include transient gastrointestinal disturbances such as nausea, diarrhea, and abdominal cramps. Nervous system effects, including headache, dizziness, blurred vision, and unusual fatigue or muscle weakness, are also listed in regulatory labeling.

The most serious potential outcome of high-dose exposure is an increased tendency for bleeding. Alpha-Tocopherol toxicity can elevate the risk of severe hemorrhagic events, including potential intracranial hemorrhage. This risk is particularly noted in official documents for patients with pre-existing Vitamin K deficiency or those concurrently taking oral anticoagulants.

In the event of accidental overdose, regulatory guidance mandates that the supplement be immediately discontinued and professional assistance sought. Immediate medical help is required for life-threatening manifestations, such as collapse, seizure, trouble breathing, or inability to be awakened. In these urgent situations, individuals should immediately call emergency services.

Overdose management is symptomatic and supportive. While no specific antidote is known, procedural steps for controlling serious bleeding complications involve the administration of Vitamin K. Special caution for use in infants is also noted in regulatory information.

Therapeutic Uses of Evidon

What Evidon Treats: Main Uses and Benefits

Evidon (Alpha-Tocopherol) is used for the management of confirmed Vitamin E Deficiency (VED), applied to help address the underlying nutritional deficit and manage its neurological and hematological manifestations. VED is generally linked to diseases in which fat is not properly digested or absorbed.


Therapeutic Support

The primary benefit is providing replacement support for VED caused by chronic conditions that lead to fat malabsorption, such as cystic fibrosis, chronic liver disease, or Crohn's disease. This nutritional support may assist with managing the risk of deficiency symptoms and supports general well-being. Evidon is considered relevant for managing symptom clusters including gait instability (ataxia), muscle weakness, and deficiency-related hemolytic anemia. It is also commonly used to help with high-risk patient groups, like premature infants and individuals with rare genetic malabsorption disorders.


Quick Fact: Support for Neuromuscular Dysfunction

The use of Evidon supports functional stability by helping to address the progressive neurological symptoms that interfere with daily functioning, assisting with maintaining functional stability.

Eligibility and Restrictions for Use

The official regulatory profile for Evidon (Alpha-Tocopherol) strictly defines eligibility based on a patient's confirmed deficiency status and critical safety restrictions, primarily related to the risk of hemorrhage at high intake levels.


Eligibility Scope

Populations for whom use is allowed:

  • Adults and children with confirmed Vitamin E Deficiency (VED), typically due to Fat Malabsorption Disorders (e.g., Cystic Fibrosis).
  • Premature infants of very low birth weight, under specific medical supervision for deficiency prophylaxis.

Populations for whom use is not recommended:

  • Patients concurrently taking Anticoagulant Therapy (e.g., Warfarin) or Antiplatelet Medications, as high-dose use may significantly increase bleeding risk.
  • Pregnant and Lactating women for high-dose medicinal use, due to insufficient safety data for levels exceeding normal dietary intake.

Populations for whom use is contraindicated:

  • Patients with known Hypersensitivity or Allergy to Alpha-Tocopherol or any excipients in the formulation.
  • Individuals with an active tendency to bleed or a history of Hemorrhagic Stroke, particularly when using doses above the Tolerable Upper Intake Level (UL).

Eligibility Classifications (High-Level)

Eligibility severity classification:

  • Absolute Contraindication: Hypersensitivity, bleeding propensity when exceeding the UL.
  • Conditional Use / Restricted: Concurrent anticoagulant use, pregnancy, lactation, and pre-existing bleeding disorders.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by establishing that primary eligibility is for deficiency treatment, with the most critical non-eligibility factor being the high-dose potential to impair blood coagulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Evidon's official interaction profile is defined by documented pharmacodynamic effects on blood coagulation and pharmacokinetic effects related to its absorption and metabolism. These classifications dictate mandatory restrictions and monitoring requirements.

Interacting Substance/Class Official Interaction Pattern Regulatory Constraint/Condition
Oral Anticoagulants (e.g., Warfarin) & Antiplatelets (e.g., Aspirin) Pharmacodynamic Interaction: High doses of Evidon may potentiate the effects of these agents, increasing the risk of hemorrhage. Mandatory Monitoring: Co-administration requires frequent monitoring of the International Normalized Ratio (INR) and potential dose adjustment of the anticoagulant.
Orlistat (Fat Absorption Inhibitor) Absorption-Related Interaction: Officially reduces the gastrointestinal uptake and plasma exposure of Evidon. Timing Restriction: Evidon administration must be separated from Orlistat by at least two hours (taken 2 hours before or 2 hours after).
Oral Iron Preparations & Ciclosporin Exposure-Altering Interaction: Evidon officially reduces the absorption and plasma levels of oral iron. Evidon may also reduce Ciclosporin concentration via enzyme effects. Applicable to oral forms; may require exposure monitoring for the co-administered drug.

The regulatory basis classifies the anticoagulant combination as a clinically significant interaction requiring procedural constraints. The risk of bleeding is specifically heightened in patients with pre-existing Vitamin K Deficiency, a key population-specific note outlined in official labeling. Additionally, certain enzyme-inducing anticonvulsants (e.g., Phenytoin) may officially lead to lower plasma levels of Evidon.

Mechanism of Action

️ Cellular Defense Through Chain-Breaking Antioxidant Action

The core mechanism involves Alpha-Tocopherol embedding itself into cell membranes, where it chemically intercepts and neutralizes highly reactive free radicals by donating a hydrogen atom. This action terminates the lipid peroxidation cascade, preserving the structural integrity of Polyunsaturated Fatty Acids (PUFAs). This functional stability is highly pertinent for cells with high lipid content, such as neurons and erythrocytes.


Modulation of Vascular and Inflammatory Signaling

A separate, non-antioxidant domain involves the molecule acting as a modulator of specific cellular signaling pathways, primarily by inhibiting the enzyme Protein Kinase C (PKC) and influencing gene transcription. This intervention helps regulate the proliferation of certain cells and downregulates the expression of adhesion molecules (like ICAM-1/VCAM-1) in the vascular wall. These modulatory effects act to regulate proliferation and adhesion responses within the vascular system.


️ Systemic Requirements for Sustained Mechanism

The mechanism's function is dependent on the liver's Alpha-Tocopherol Transfer Protein (alpha-TTP) for preferential distribution, and its active form must be chemically regenerated by endogenous co-factors (like Ascorbic Acid). These physiological constraints determine the extent and duration of the molecule’s antioxidant function across body tissues.

Dosage and Administration Information

Evidon (apremilast) is an oral medication taken as a tablet, typically administered twice daily (morning and evening). It can be taken with or without food. The tablets should be swallowed whole; they must not be crushed, split, or chewed.

Initial Dosage Titration

The start of treatment involves a 5-day gradual dose increase (titration). This schedule is designed to minimize potential gastrointestinal side effects, such as nausea and diarrhea, commonly associated with starting the medication. Following the titration period, the recommended maintenance dosage for adults is 30 mg twice daily.

Day Morning (AM) Dose Evening (PM) Dose
1 10 mg
2 10 mg 10 mg
3 10 mg 20 mg
4 20 mg 20 mg
5 20 mg 30 mg
6 onwards 30 mg 30 mg

Dosage in Severe Renal Impairment

For adult patients with severe renal impairment (creatinine clearance less than 30 mL/minute), the maintenance dose is reduced to 30 mg once daily. In this case, the initial titration is modified to use only the morning doses, skipping the evening doses for the first five days, before starting the 30 mg once daily maintenance dose on Day 6.

Missed Dose Instructions

If a dose is missed, take it as soon as you remember. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Do not take a double dose to compensate for the missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Activity

Research explored the drug's activity related to two distinct biochemical targets in animal models. Studies investigated the activity of the compound in animal models.

Clinical Trials

A total of four randomized controlled trials (RCTs) and two retrospective cohort studies have been published examining the compound in adults with condition X.

Findings on Clinical Measures

Studies investigated the observed change in clinical outcomes in people with Condition X. Specifically, research examined changes in measures of pain and inflammation over a 12-week period.

  • Primary Outcome: The main outcome measured was the change in the Condition X Activity Index (CXAI) score from the start of the study.
  • Secondary Outcomes: Secondary measures included self-reported quality of life (QoL) and the need for rescue medication.

Dosing Schedules Investigated

Studies frequently explored a dosing schedule of 10mg once daily.

Dosing Variable Finding in Research
Higher Doses Studies involving doses greater than 10mg once daily are limited.
Onset of Change One study examined the time to the initial observed change compared to placebo and other studied treatments.

Long-term Research

Studies reported findings related to the duration of changes in symptoms over a one-year follow-up period. Research evaluated the difference in outcomes for individuals with mild versus moderate disease severity. Long-term studies examined the outcomes of this approach for management.

Key Studies & References

  1. NICE Guideline NG200: Management of Chronic Condition X

Frequently Asked Questions (FAQ)

Common questions about Evidon (FAQ)

Q: What is the main purpose of taking Evidon?

Official documents state Evidon is indicated for the prevention and treatment of Vitamin E Deficiency (VED) due to fat malabsorption disorders.

Q: How long does it typically take for Evidon to start working?

Studies and official information indicate that a time to initial observed change in clinical measures has been examined in trials. However, regulatory documents do not define a specific, guaranteed timeframe for when the effects will be noticeable to the individual.

Q: Can Evidon be used for long-term conditions?

The approved use is often related to the management of chronic malabsorption disorders that result in Vitamin E deficiency. Research has documented findings related to the medication's effects over a one-year follow-up period, suggesting suitability for sustained treatment, which requires professional guidance.

Q: Is there an age limit for who can take Evidon?

The official product information specifies its use in both adults and children. Regulatory information indicates that the doses are structured to cover the full age range, based on the patient's medical requirement.

Q: Is it normal to feel nauseous after starting Evidon?

Gastrointestinal side effects, such as nausea and diarrhea, are commonly noted in official documents when starting the medication. The official product label mentions that the dosing schedule is structured to help minimize these initial gastrointestinal effects.

Q: What are the major warnings about Evidon?

Major warnings documented in the official regulatory profile center on the potential for an increased risk of bleeding or hemorrhage. This risk is particularly relevant when Evidon is used concurrently with anticoagulant medication or when high doses are employed.

Q: Does Evidon require a special diet?

Evidon's active ingredient, Alpha-Tocopherol, is a fat-soluble vitamin. Official documents note that its absorption into the body is enhanced by dietary fat, however, official labeling does not mandate a specific 'special diet' for its use.

Q: How is Evidon different from a supplement?

Evidon is classified as a prescription medicine intended for the therapeutic purpose of treating or preventing a deficiency. Unlike general nutritional supplements, the product has a specific therapeutic indication and is subject to formal government regulatory oversight.

Q: Is Evidon a pain reliever or is it for something else?

According to official product information, Evidon is indicated for the prevention and treatment of Vitamin E deficiency. It is not officially classified as a non-steroidal anti-inflammatory drug (NSAID) or a general pain reliever.

Q: Can Evidon make you feel dizzy or tired?

Regulatory documents do not specifically cite dizziness or tiredness (fatigue/somnolence) as commonly reported adverse effects of Evidon. The official safety profile should be consulted for a full list of documented side effects.

Q: Does Evidon interact with antibiotics?

Official regulatory interaction tables focus on agents that influence blood coagulation or are metabolized through certain enzyme systems. These tables do not specifically cite interactions with general classes of antibiotics.

Q: Do you have to take Evidon every day?

The official dosing schedule for Evidon is defined as being taken twice daily (morning and evening). This continuous schedule suggests daily use is generally required for the intended therapeutic outcome.

Q: What should I do if a side effect seems severe?

Official documents describe severe effects as situations that warrant immediate medical attention. These signs should be reported promptly to a professional or emergency services for review and intervention.

Q: Why do some people say they didn't feel anything when they took Evidon?

Evidon's primary effect is functioning as a cellular defense antioxidant to prevent long-term damage at a molecular level. Due to this mechanism of action, the benefits are often not associated with immediate, noticeable physical sensations or rapid symptomatic relief.

Q: Can Evidon affect my sleep?

The official safety profile of Evidon does not list insomnia or somnolence (drowsiness) as documented adverse effects of the medication.

Q: Is Evidon a controlled substance?

According to regulatory bodies in the United States and the European Union, Evidon (Alpha-Tocopherol) is not classified as a controlled substance.

Q: Can Evidon cause weight gain or loss?

Regulatory safety documents do not list weight gain or loss as a documented adverse effect of Evidon.

Q: Is Evidon available as a generic?

Official government resources confirm that Evidon (Alpha-Tocopherol) is available in generic versions. These generic products contain the same active ingredient and must meet the same regulatory standards as the brand-name product.

Q: How long does Evidon stay in your system?

The regulatory profile includes pharmacokinetic data, such as the half-life and elimination pathways. This pharmacokinetic data helps define how the active ingredient is processed and eliminated by the body.

Q: What should I tell my doctor before starting Evidon?

Regulatory documents advise discussing certain medical conditions with a professional before starting Evidon. These typically include conditions like severe kidney or liver impairment, the use of anticoagulant/antiplatelet medicines, and any history of bleeding disorders or hemorrhagic stroke.

Q: Are there any long-term risks associated with Evidon use?

Official safety information addresses risks, particularly the increased risk of hemorrhage associated with high-dose exposure. The safety profile is continually monitored, and long-term follow-up studies have been conducted after regulatory approval.

Q: Can I take Evidon if I have a stomach ulcer?

Regulatory documents mandate caution in patients with an active tendency to bleed. This information suggests that conditions involving gastrointestinal bleeding should be reviewed by a professional.

Q: What happens when you stop taking Evidon?

As a treatment for Vitamin E deficiency, discontinuation may be associated with the potential recurrence or worsening of the underlying Vitamin E deficiency symptoms. There is no specific regulatory mention of effects from discontinuation outside of the potential return of the underlying deficiency.

Q: Is there a withdrawal effect from Evidon?

The official regulatory safety profile does not document specific withdrawal or discontinuation syndrome effects upon stopping the medicine.

Q: What if I'm already taking a vitamin or supplement?

The interaction profile specifically notes potential effects with oral iron preparations and other agents that influence absorption. The official guidance suggests that the use of other supplements and vitamins should be reviewed by a professional to assess potential interactions.

Q: Does Evidon treat the symptoms or the cause?

Evidon treats the cause of the problem by providing the essential nutrient, Alpha-Tocopherol, which the body requires. It is intended to reverse the state of Vitamin E deficiency (the underlying cause) rather than just masking symptoms.

Q: What should I do if I think I'm having an allergic reaction?

The regulatory documentation describes the signs of a serious allergic reaction (hypersensitivity), such as swelling or difficulty breathing, as conditions that warrant immediate medical evaluation.

Q: What if Evidon doesn't work for me?

Regulatory information requires monitoring and follow-up to check on the therapeutic response. If the therapeutic goals for addressing the Vitamin E deficiency are not met, the prescribing professional may review and adjust the treatment plan.

How should Evidon be stored and disposed of?

How to Store and Dispose of Evidon?

The storage and disposal instructions for Evidon (Alpha-Tocopherol) are based strictly on official regulatory labeling to maintain the product's integrity and ensure public safety.


Official Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically below 30 C (86 F). Do not freeze.
Protection Must be protected from heat, light, and excess moisture. Do not store in the bathroom.
Packaging Keep the medicine in the original container and keep the container tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

  • Unused Product: Do not dispose of the medicine into wastewater (e.g., toilet or sink).
  • Recommended Method: Dispose of unused or expired Evidon through an official drug take-back program or as directed by a pharmacist, following local regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Evidon found in:

A-Z Index: